PTSD Progress Note and Privileged Note: Clinical Case Study
This paper presents a psychiatric progress note and privileged note for a 33-year-old African-American woman diagnosed with PTSD following intimate partner violence. After four weeks of treatment with Sertraline 25 mg and weekly cognitive behavioral therapy (CBT), the client shows minimal improvement. The paper documents her subjective complaints, clinical impressions, safety status, and psychosocial functioning. It then outlines revised treatment recommendations, including an increased Sertraline dosage, more frequent CBT sessions, and interdisciplinary collaboration with a nutritionist and family counselor. A separate privileged note addresses family dynamics, anger management, and self-esteem. The paper also distinguishes between progress notes and privileged notes under HIPAA privacy guidelines.
- Case Summary and Background: PTSD diagnosis and initial treatment overview
- Subjective Report and Treatment Compliance: Client's self-reported symptoms and medication adherence
- Clinical Impressions and Safety: Clinician observations and safety screening findings
- Analysis and Treatment Rationale: Evidence-based reasoning for maintaining Sertraline
- Revised Treatment Plan and Recommendations: Dosage increase, CBT frequency, and referrals
- Privileged Note: Family and Psychosocial Considerations: Private notes on family dynamics and self-esteem
- Progress Notes vs. Privileged Notes: Legal and clinical distinction between note types
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The case study follows a structured clinical documentation format — subjective content, objective findings, analysis, and plan — mirroring real-world psychiatric progress notes, which lends it professional authenticity.
- The paper integrates evidence-based rationale for treatment decisions, citing peer-reviewed literature on SSRI timelines and CBT session frequency to justify each recommendation.
- The privileged note section adds conceptual depth by distinguishing between two types of clinical documentation and explaining their different legal and ethical statuses under HIPAA.
Key academic technique demonstrated
The paper demonstrates clinical reasoning through the SOAP (Subjective, Objective, Assessment, Plan) documentation framework. Rather than simply describing symptoms, the writer connects clinical observations to evidence-based decisions, such as maintaining Sertraline rather than switching SSRIs because the six-to-eight-week therapeutic window has not elapsed. This shows the ability to apply biomedical and behavioral evidence to individualized patient care.
Structure breakdown
The paper is divided into two parts: a formal progress note (Part 1) and a privileged note (Part 2). Part 1 proceeds through standard clinical documentation sections — case summary, subjective content, compliance, psychosocial context, safety, clinical impressions, analysis, and plan. Part 2 addresses sensitive family information and explains the theoretical distinction between progress notes and privileged notes. Together, the two parts illustrate complete psychiatric case management documentation at the graduate clinical level.
Case Summary and Background
Client Y is a 33-year-old African-American female with two children aged 3 and 5, married to a 39-year-old Hispanic male. She presents following a referral by her sister, who believes she is under severe emotional distress. Symptoms at the time of presentation included depressed mood, inability to concentrate, nightmares, sleeping difficulties, and heightened irritability. The client reported that symptoms began four months earlier, after a violent encounter with her husband that resulted in serious injury.
Client Y was diagnosed with post-traumatic stress disorder (PTSD) and placed on Sertraline (Zoloft) 25 mg once daily in addition to once-weekly cognitive behavioral therapy (CBT) sessions. The goal of treatment is to ensure that Client Y regains control over her life and develops skills to address her symptoms. Four weeks later, the client shows minimal response to treatment, and PTSD symptoms remain present. No modifications have been made to the treatment plan thus far.
Subjective Report and Treatment Compliance
The client reports that she is still unable to concentrate, feels depressed most of the day, and has noticed no improvement in her nightmares. She describes feeling like a "ship lost at sea — afraid of a pirate attack at any time," as she constantly fears she could upset her husband and provoke another violent attack. She reports being able to fall asleep more easily over the past two weeks and no longer experiences night chills or sweating, though she still fears going to bed because the nightmares persist. She states she is "willing to do anything for the nightmares to go away and for her days and those of her family to be bright again." She is also concerned that the prescribed medication is "working too slowly."
Regarding treatment compliance, the client reports that she had been taking her medication as prescribed until a week ago, when she began to feel it had "no impact." She now takes the medication only when she remembers. The client has not taken any other medication since beginning treatment with Sertraline.
In terms of psychosocial functioning, her relationship with her husband is deteriorating, as she reports that she "no longer loves her husband like she used to." Her interactions with male clients have been severely affected, and she fears this is hurting her business. She is concerned that she may lose key clients, as she has had to limit associations with male clients in particular. Her relationship with her children has also suffered; she no longer takes time to cook meals for them or spend time with them on weekends.
Clinical Impressions and Safety
The client is well-groomed but presents as irritable and distracted. She is fully communicative, although her speech rate is slow and at times incoherent. She consistently avoids eye contact, and her reasoning and thought processes are occasionally illogical. She displays a depressed mood and shows delusional thinking, particularly regarding how married couples ought to relate to one another. Insight and judgment are intact. The client denies homicidal or suicidal ideation and appears aware of her existence, though she lacks insight into some of her own thoughts.
Regarding safety, the client does not report any adverse effects from Sertraline. She reports no heart palpitations, chest pain, or breathing difficulties. No clinical emergencies have been identified.
Analysis and Treatment Rationale
The client has not reported any adverse effects from Sertraline thus far. While this may be a positive sign, it could also indicate insufficient dosage. Although the expected treatment goal has not been realized, it is not advisable to switch to a different selective serotonin reuptake inhibitor (SSRI) at this stage, as the effectiveness of Sertraline has not been adequately tested. Clinical trials have shown that treatment gains from SSRIs are typically realized between six and eight weeks (Sanchez et al., 2014; Fergusson, 2013). The most appropriate course of action, therefore, is to maintain Sertraline while increasing the dosage for an additional four weeks.
Revised Treatment Plan and Recommendations
Client Y and the PMHNP agree that little progress has been made toward the expected treatment goal. The PMHNP recommends the following:
i) Increase the dosage of Sertraline from 25 mg to 50 mg daily. The absence of adverse effects at the current dose, combined with the lack of therapeutic response, supports a dose increase within the standard titration protocol.
ii) Introduce twice-weekly CBT sessions to replace the current once-weekly sessions. Studies have shown that twice-weekly CBT sessions are more effective and lead to more rapid recovery of depressive symptoms than once-weekly sessions (Bruijniks et al., 2015).
iii) Client returns for review in four weeks. Client agrees with these recommendations.
Short-Term Goal: With the increased Sertraline dosage and twice-weekly CBT sessions, the PMHNP expects Client Y to report a 50 percent remission of PTSD symptoms by the time of the next visit.
Collaboration with Other Professionals:
The PMHNP will contact a nutritionist the following week to assist the client with weight management. Weight gain is a common adverse effect of Sertraline, and there is a risk that the client's existing obesity may worsen with sustained SSRI use (Shi et al., 2017). The PMHNP will also contact a family counselor the following week to plan joint therapy and anger-management sessions for the client and her husband.
Referrals: The PMHNP refers the client to a local fitness program to support weight management.
Consent and Administrative Details: Client willingly consents to the prescribed treatment plan. Treatment costs are to be covered either out-of-pocket or through health insurance. In the event of loss of insurance coverage, the client will be notified and treatment will be terminated within 14 days of such notification. The client is instructed to return in four weeks or sooner if necessary. Time spent counseling: 45–50 minutes. Session start: 11:00 a.m. Session end: 11:50 a.m.
References
Bruijniks, S. E., Bosmans, J., Peters, F., & Huibers, M. (2015). Frequency and change mechanisms of psychotherapy among depressed patients: Study protocol for a multicenter randomized controlled trial comparing twice-weekly versus once-weekly sessions of CBT and IPT. BMC Psychiatry, 15(1), 137–147.
Corley, S. O. (2013). Protection for psychotherapy notes under HIPAA privacy rule: As private as a hospital gown. The Journal of Law-Medicine, 22(2), 489–534.
Fergusson, J. M. (2001). SSRI antidepressant medications: Adverse effects and tolerability. Primary Care Companion to the Journal of Clinical Psychiatry, 3(1), 22–27.
Sanchez, C., Reines, E. H., & Montgomery, S. (2014). A comparative review of escitalopram, paroxetine, and sertraline. International Clinical Psychopharmacology, 29(4), 185–196.
Shi, A., Atlantis, E., Taylor, A. W., Gill, T., Price, K., Appleton, S., Wong, M., & Licinio, J. (2017). SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: Results from a 4-year Australian follow-up. BMJ Open, 7(8).
Always verify citation format against your institution’s current style guide requirements.